Bicara Therapeutics (BCAX) Share-based Compensation (2023 - 2026)

Bicara Therapeutics has reported Share-based Compensation for 4 years, with the latest figure at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 69.75% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $17.4 million (up 79.5% YoY), and the FY2025 full-year result was $15.0 million, up 102.87% from the prior year.
• Share-based Compensation for Q1 2026 stood at $5.9 million, up from $4.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.9 million in Q1 2026, with the low at $765000.0 in Q4 2023.
• Historically, Share-based Compensation has averaged $2.9 million across 4 years, with a median of $3.3 million in 2024.
• Annual changes were most pronounced in 2024 — Share-based Compensation jumped 315.82% — and 2025, when it soared 39.86%.
• Bicara Therapeutics' Share-based Compensation stood at $765000.0 in 2023, then jumped by 315.82% to $3.2 million in 2024, then soared by 39.86% to $4.4 million in 2025, then jumped by 31.67% to $5.9 million in 2026.
• The last three Share-based Compensation figures came in at $5.9 million (Q1 2026), $4.4 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.